Clinical Effect of Gonadotropins of Human Origin. Case Report with a Two-Year Follow-up

Publisher Website
Google Scholar
Abstract
The ovarian response to human gonadotropins of pituitary and urinary origin was studied in one female patient, age 27, who had secondary amenorrhea. During a 2-year period, the patient received 10 courses of medication. The gonadotropin preparations were given alone and in combination with human chorionic gonadotropin (HCG). In addition, the patient received one course of medication with HCG alone. No generalized reactions occurred. Local reactions such as redness and pain at the injection site were noted with only one of the preparations employed(Pergonal 22-C). All preparations of human gonadotropin used contained FSH and LH activity. Their FSH activity was expressed in terms of NIH-FSH-SI. The level of ovarian response was apparently dependent upon the relative amounts of FSH and LH activity contained in the dose employed. Doses of a potency approximately equivalent to 2.5–4 mg of NIH-FSH-SI/day, in combination with HCG, were without effect. Doses of a potency approximately equivalent to 3–6 mg of NIHFSH-SI/day, in combination with HCG, induced ovarian stimulation, as judged by the levels of urinary estrogens and pregnanediol excretion. Doses of a potency approximately equivalent to 5–13 mg of NIHFSH-SI/day, in combination with HCG, brought about an even greater ovarian response, as judged by the same indices. Urinary 17-KS and 17-OHCS were not affected. Menstrual bleeding occurred 15–24 days after initiation of combined therapy. Repeated administration of the preparations elicited an ovarian response suggesting absence of refractoriness.

This publication has 7 references indexed in Scilit: